Posttransplant diabetes and hypertension: Pathophysiologic insights and therapeutic rationale

Current Diabetes Reports

Volumn 8, Issue 3, 2008, Pages 221-227

  Salifu, Moro O ^a   Tedla, Fasika ^b   Aytug, Serhat ^b   Hayat, Amir ^b   McFarlane, Samy I ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INSULIN; MYCOPHENOLIC ACID; ORAL ANTIDIABETIC AGENT; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; VERAPAMIL;

ADVERSE OUTCOME; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; DIAGNOSTIC TEST; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FLUID RETENTION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ARTERY STENOSIS; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; NEPHROTOXICITY; NEW ONSET DIABETES AFTER TRANSPLANTATION; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT HYPERTENSION; PREOPERATIVE EVALUATION; RENAL GRAFT DYSFUNCTION; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTEMIC VASCULAR RESISTANCE; DIABETES MELLITUS; PATHOLOGY;

DIABETES MELLITUS; HUMANS; HYPERTENSION; KIDNEY TRANSPLANTATION;

EID: 52649114354     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0038-6     Document Type: Review

References (56)

1. Jindal RM: Posttransplant diabetes mellitus - a review. Transplantation 1994, 58:1289-1298.
2. Salifu MO, Tedla. F, Murty PV, et al.: Challenges in the diagnosis and management of new-onset diabetes after transplantation. Curr Diab Rep 2005, 5:194-199.
3. Tedla F, Hayashi R, McFarlane SI, Salifu MO: Hypertension after renal transplant. J Clin Hypertens (Greenwich) 2007, 9:538-545.
4. Ojo AO, Hanson JA, Wolfe RA, et al.: Long-term survival in renal transplant recipients with graft function. Kidney Int 2000, 57:307-313.
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
6. Davidson J, Wilkinson A, Dantal J, et al.: New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003, 75:SS3-SS24.
7. Montori VM, Basu A, Erwin PJ, et al.: Posttransplantation diabetes: a systematic review of the literature Diabetes Care 2002, 25:583-592.
8. Heisel O, Heisel R, Balshaw R, Keown P: New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004, 4:583-595.
9. Vesco L, Busson M, Bedrossian J, et al.: Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors. Transplantation 1996, 61:1475-1478.
10. Sumrani NB, Delaney V, Ding Z, et al.: Diabetes mellitus after renal transplantation in the cyclosporine era - an analysis of risk factors. Transplantation 1991, 51:343-347.
11. Bloom RD, Rao V, Weng F, et al.: Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002, 5:1374-1380.
12. Nam JH, Mun JI, Kim SI, et al.: β-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001, 71:1417-1423.
13. von Kiparski A, Frei D, Uhlschmid G, et al.: Post-transplant diabetes mellitus in renal allograft recipients: a matched-pair control study. Nephrol Dial Transplant 1990, 5:220-225.
14. Mathew JT, Rao M, Job V, et al.: Post-transplant hyperglycaemia: a study of risk factors. Nephrol Dial Transplant 2003, 18:164-171.
15. Andrews RC, Walker BR: Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci 1999, 96:513-523.
16. Wajngot A, Giacca A, Grill V, et al.: The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci U S A 1992, 89:6035-6039.
17. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H: Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 1997, 40:1439-1448.
18. Hollander AA, Hene RJ, Hermans J, et al.: Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997, 8:294-301.
19. Hricik DE, Bartucci MR, Moir EJ, et al.: Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991, 51:374-377.
20. Oetjen E, Baun D, Beimesche S, et al.: Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice. Mol Pharmacol 2003, 63:1289-1295.
21. Duijnhoven EM, Boots JM, Christiaans MH, et al.: Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 2001, 12:583-588.
22. Hjelmesaeth J, Hartmann A, Kofstad J, et al.: Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Medical Department B, National Hospital, University of Oslo, Norway. Transplantation 1997, 64:979-983.
23. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003, 3:178-185.
24. Fernandez-Fresnedo G, Escallada R, de Francisco AL, et al.: Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients. Transplant Proc 2003, 35:700.
25. Kasiske BL, Vazquez MA, Harmon WE, et al.: Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000, 11(Suppl 15):S1-S86.
26. Grinyo JM, Cruzado JM: Steroid or calcineurin inhibitorsparing immunosuppressive protocols. Contrib Nephrol 2005, 146:30-42.
27. Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A metaanalysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000, 11:1910-1917.
28. Nematalla AH, Bakr MA, Gheith OA, et al.: Steroidavoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study. Exp Clin Transplant 2007, 5:673-679.
29. Abouljoud MS, Kumar MS, Brayman KL, et al.: Neoral rescue therapy in transplant patients with intolerance to tacrolimus. Clin Transplant 2002, 16:168-172.
30. First MR, Neylan JF, Rocher LL, Tejani A: Hypertension after renal transplantation. J Am Soc Nephrol 1994, 4(8 Suppl):S30-S36.
31. Textor SC, Canzanello VJ, Taler SJ, et al.: Cyclosporineinduced hypertension after transplantation. Mayo Clin Proc 1994, 69:1182-1193.
32. Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998, 53:217-222.
33. Textor SC, Wiesner R, Wilson Dj, et al.: Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993, 55:1332-1339.
34. Moss NG, Powell SL, Falk RJ: Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad Sci U S A 1985, 82:8222-8226.
35. McNally PG, Feehally J: Pathophysiology of cyclosporin A nephrotoxicity: experimental and clinical observations. Nephrol Dial Transplant 1992, 7:791-804.
36. Brem AS: Insights into glucocorticoid-associated hypertension. Am J Kidney Dis 2001, 37:1-10.
37. Ahsan N, Hricik D, Matas A, et al.: Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999, 68:1865-1874.
38. Fernandez-Fresnedo G, Palomar R, Escallada R, et al.: Hypertension and long-term renal allograft survival: effect of early glomerular filtration rate. Nephrol Dial Transplant 2001, 16(Suppl 1):105-109.
39. Brod J, Bahlmann J, Cachovan M, et al.: Mechanisms for the elevation of blood pressure in human renal disease. Preliminary report. Hypertension 1982, 4:839-844.
40. Salifu MO, Haria DM, Badero O, et al.: Challenges in the diagnosis and management of renal artery stenosis. Curr Hypertens Rep 2005, 7:219-227.
41. Lacombe M: Arterial stenosis complicating renal allotransplantation in man: a study of 38 cases. Ann Surg 1975, 181:283-288.
42. Aslam S, Salifu MO, Ghali H, et al.: Common iliac artery stenosis presenting as renal allograft dysfunction in two diabetic recipients. Transplantation 2001, 71:814-817.
43. Guidi E, Bianchi G, Rivolta E, et al.: Hypertension in man with a kidney transplant: role of familial versus other factors. Nephron 1985, 41:14-21.
44. Strandgaard S, Hansen U: Hypertension in renal atlograft recipients may be conveyed by cadaveric kidneys from donors with subarachnoid haemorrhage. Br Med J (Clin Res Ed) 1986, 292:1041-1044.
45. Hausberg M, Kosch M, Harmelink P, et al.: Sympathetic nerve activity in end-stage renal disease. Circulation 2002, 106:1974-1979.
46. Curtis JJ, Luke RG, Diethelm AG, et al.: Benefits of removal of native kidneys in hypertension after renal transplantation. Lancet 1985, 2:739-742.
47. Midtvedt K, Hartmann A, Bentdal O, et al.: Bilateral nephrectomy simultaneously with renal allografting does not alleviate hypertension 3 months following living-donor transplantation. Nephrol Dial Transplant 1996, 11:2045-2049.
48. Mailloux LU, Levey AS: Hypertension in patients with chronic renal disease. Am J Kidney Dis 1998, 32(5 Suppi 3): S120-S141.
49. Olyaei AJ, deMattos AM, Bennett WM: A practical guide to the management of hypertension in renal transplant recipients. Drugs 1999, 58:1011-1027.
50. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157:2413-2446.
51. Martin JE, Daoud AJ, Schroeder TJ, First MR: The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics 1999, 15:317-337.
52. Stigant CE, Cohen J, Vivera M, Zaltzman JS: ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000, 35:58-63.
53. Hiremath S, Fergusson D, Doucette S, et al.: Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007, 7:2350-2360.
54. Sinclair NR: Low-dose steroid therapy in cyclosporinetreated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992, 147:645-657.
55. Beecroft JR, Rajan DK, Clark TW, et al.: Transplant renal artery stenosis: outcome after percutaneous intervention. J Vasc Interv Radiol 2004, 15:1407-1413.
56. Bertoni E, Zanazzi M, Rosat A, et al.: Efficacy and safety of Palmaz stent insertion in the treatment of renal artery stenosis in kidney transplantation. Transpl Int 2000, 13(Suppl 1):S425-S430.